TY - JOUR
T1 - Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy
T2 - A Review of the Literature
AU - Schonck, Willemijn A. M.
AU - Stroes, Erik S. G.
AU - Hovingh, G. Kees
AU - Reeskamp, Laurens F.
N1 - Publisher Copyright: © The Author(s) 2024.
PY - 2024/2
Y1 - 2024/2
N2 - Increased plasma levels of low-density lipoprotein cholesterol (LDL-C) are causally associated with atherosclerotic cardiovascular disease (ASCVD), and statins that lower LDL-C have been the cornerstone of ASCVD prevention for decades. However, guideline-recommended LDL-C targets are not achieved in about 60% of statin users. Proprotein convertase subtilisin/kexin type 9 (PCSK9)-targeted therapy effectively lowers LDL-C levels and has been shown to reduce ASCVD risk. A growing body of scientific and clinical evidence shows that PCSK9-targeted therapy offers an excellent safety and tolerability profile with a low incidence of side effects in the short term. In this review, we present and discuss the current clinical and scientific evidence pertaining to the long-term efficacy and tolerability of PCSK9-targeted therapy.
AB - Increased plasma levels of low-density lipoprotein cholesterol (LDL-C) are causally associated with atherosclerotic cardiovascular disease (ASCVD), and statins that lower LDL-C have been the cornerstone of ASCVD prevention for decades. However, guideline-recommended LDL-C targets are not achieved in about 60% of statin users. Proprotein convertase subtilisin/kexin type 9 (PCSK9)-targeted therapy effectively lowers LDL-C levels and has been shown to reduce ASCVD risk. A growing body of scientific and clinical evidence shows that PCSK9-targeted therapy offers an excellent safety and tolerability profile with a low incidence of side effects in the short term. In this review, we present and discuss the current clinical and scientific evidence pertaining to the long-term efficacy and tolerability of PCSK9-targeted therapy.
UR - http://www.scopus.com/inward/record.url?scp=85183059634&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s40265-024-01995-9
DO - https://doi.org/10.1007/s40265-024-01995-9
M3 - Review article
C2 - 38267805
SN - 0012-6667
VL - 84
SP - 165
EP - 178
JO - Drugs
JF - Drugs
IS - 2
ER -